DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jesse Pound - 3 NASH - 3 John Riccitiello - 2 Rivian - 2 Davidson - 2 Goldman Sachs - 2 — - 2 Samantha Subin - 2
Top related locs:
U.S Israel Nash Xpeng China Underperform ORLY Caribou
Top related orgs:
Akero Therapeutics - 6 UBS - 4 JPMorgan - 3 Deutsche Bank - 3 Therapeutics - 3 U.S . Army - 2 LSEG - 2 Arm Holdings - 2

Search resuls for: "Akero Therapeutics"


10 mentions found


☆ Cramer’s Stop Trading: Akero Therapeutics
  + stars: | 2024-02-06 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer’s Stop Trading: Akero TherapeuticsCNBC’s Jim Cramer explains why he is keeping an eye on shares of Akero Therapeutics.
Persons: Jim Cramer Organizations: Akero Therapeutics
☆ Stocks making the biggest moves premarket: Palantir, PepsiCo, Rivian and more
  + stars: | 2023-10-10 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
Palantir Technologies — Shares of the data analytics company added 2.3% on news that the U.S. Army awarded the company a $250 million contract to test and develop artificial intelligence and machine learning. Unity Software — The game engine stock surged nearly 6% after the company said CEO John Riccitiello would retire. Rivian Automotive — Shares of the electric truck company rose 3% in premarket trading after UBS upgraded Rivian to buy from neutral. PepsiCo — Shares of the beverage giant added roughly 1% after a third-quarter earnings beat. Akero Therapeutics — The biotech company plummeted more than 63% after reporting initial trial data related to a Phase 2B study of cirrhosis drug efruxifermin.
Persons: John Riccitiello, James M, Whitehurst, Rivian, Davidson, Goldman Sachs, —, Jesse Pound, Sarah Min Organizations: U.S . Army, Software, UBS, PepsiCo —, LSEG, Ameris, Bancorp, Arm Holdings, JPMorgan, Deutsche Bank, Akero Therapeutics
☆ Stocks making the biggest moves midday: Block, Truist, PepsiCo, Rivian and more
  + stars: | 2023-10-10 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +3 min
Solar companies — Shares of solar companies rallied Tuesday, putting the Invesco Solar ETF (TAN) on pace for its best day since March 21. The defense and aerospace companies rose Monday after the Israel-Hamas war began over the weekend. Rivian — Shares of the electric vehicle manufacturer rose more than 5% after UBS upgraded the stock to buy from neutral. Block — Shares added 5.5% after Bank of America reiterated its buy rating on the payments stock. Unity Software — The video game software company added 3.2%.
Persons: Skechers, SolarEdge, Hannon Armstrong, Baird, Rivian, Joseph Spak, Semafor, Jason Kupferberg, efruxifermin, John Riccitiello, James Whitehurst, Davidson, — CNBC's Pia Singh, Tanaya Macheel, Jesse Pound, Michelle Fox, Lisa Kailai Han, Samantha Subin Organizations: UBS, Palantir Technologies, U.S . Army, PepsiCo, LSEG, Sustainability, Bank of America, Electronic Arts, EA's FIFA, Technologies, Northrop Grumman, Hamas, Truist, Therapeutics, Unity Software, Unity, Arm, Deutsche Bank, JPMorgan, Arm Holdings Locations: Israel
☆ This biotech stock can rally more than 70% with its fatty liver disease treatment, UBS says
  + stars: | 2023-08-28 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Akero Therapeutics could be a winner in the race to treat non-alcoholic steatohepatitis, a potentially life-threatening liver disease. Nash is a severe form of fatty liver disease which can cause inflammation of the liver and fibrosis, or scarring, of the liver. The disease can also lead to cirrhosis, in which the liver is permanently damaged. Individuals with Nash are part of the 20% of adults in the U.S. who have NAFLD, or non-alcoholic fatty liver disease. AKRO YTD mountain Akero Therapeutics stock.
Persons: steatohepatitis, Eliana Merle, Akero, Nash, NASH, Merle, NASH cirrhotics, — CNBC's Michael Bloom Organizations: U.S . Food, Drug Administration, Therapeutics Locations: U.S, Nash
☆ Stocks making the biggest moves midday: RPT Realty, Mister Car Wash, Boston Scientific, 3M and more
  + stars: | 2023-08-28 | by ( Sarah Min | ) www.cnbc.com   time to read: +3 min
RPT Realty — RPT Realty shares surged 17% after Kimco Realty, an operator of open-air shopping centers, said it would acquire the real estate investment trust in a roughly $2 billion all-stock deal. Mister Car Wash — The car wash stock advanced 6.1% on the back of an upgrade to overweight from neutral by Piper Sandler. Alibaba Group , JD.com — Alibaba and JD.com each added more than 2% after the Chinese government announced measures to boost its stock market, including reducing a tax on trading. Xpeng — Shares of the Chinese electric car company jumped 5.3% after the firm said it is buying Didi's smart electric car development business in an exchange of shares worth $744 million. Meanwhile, Xpeng said it plans to develop an electric car for launch next year under a new mass market brand.
Persons: Conor Flynn, Piper Sandler, — CrowdStrike, Morgan Stanley, —, Xpeng, Wells, Sarah Akers, Micron Technology — Stocks, — CNBC's Alexander Harring, Hakyung Kim, Yun Li, Jesse Pound, Pia Singh, Samantha Subin Organizations: RPT, Realty, Kimco Realty, Boston, Boston Scientific, Bloomberg, 3M, Akero Therapeutics, Therapeutics, UBS, Alibaba, Micron Technology —, Micron Technology, Marvell Technology, Semiconductors Locations: Xpeng
☆ Here are Monday's biggest analyst calls: Tesla, Netflix, Disney, Amazon, Alphabet, Nike, Costco & more
  + stars: | 2023-08-28 | by ( Michael Bloom | ) www.cnbc.com   time to read: +8 min
UBS reiterates Netflix as buy UBS said it's standing by its buy rating on shares of the streaming giant. Morgan Stanley reiterates Ambarella as overweight Morgan Stanley said it's bullish on shares of the semiconductor company heading into earnings this week. " UBS reiterates Disney as buy UBS said it's standing by its buy rating on shares of the entertainment giant. Morgan Stanley downgrades CrowdStrike to equal weight from overweight Morgan Stanley said it's cautious heading into earnings later this week. Morgan Stanley names LifeStance Health Group a top pick Morgan Stanley said shares of the behavioral health company are compelling.
Persons: Tesla, Canaccord, it's bullish, it's, Morgan Stanley, Ambarella, JMP, Piper Sandler, Piper, Bernstein, L3Harris, Evercore, Jefferies, Morgan Stanley downgrades CrowdStrike, Zimmer, BTIG, Wells, Dwight, Truist, Wolfe, Stifel, defensives Organizations: UBS, Netflix, Disney, Pagaya Technologies, MCW, OW, JetBlue, " Bank of America, Bank of America, Akero Therapeutics, RBC, Tetra Tech, Tech, Amazon, LifeStance Health, Mobility, UGI Corporation, TAM, Nike, NIKE, Endeavor Group, Media, Entertainment, Costco, AutoZone, Walmart Locations: China, Underperform, ORLY
☆ As weight loss drug stocks rallied on a landmark study, these stocks were over sold, analysts say
  + stars: | 2023-08-11 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +8 min
However, the pharmaceutical companies are making the case that weight loss can improve health, and possibly lower health-care costs over time. But analysts have said the news isn't all bad for such stocks, and many were fell too low on Tuesday. Deutsche Bank analyst Imron Zafar estimated Thursday that bariatric surgery accounts for about 5% of Intuitive Surgical's U.S. robotic surgery business, but has been driving much of the company's growth. Some of the surgeons Zafar spoke with said any drop off in bariatric surgery was likely to be offset by increased use of the robot for other procedures. But they expect the drugs will remain necessary because GLP-1 drugs have yet to show they improve fibrosis, which is associated with NASH.
Persons: nonalcoholic steatohepatitis, NASH, Abbott, Robbie Marcus, Marcus, Marcus doesn't, Goldman Sachs, Goldman, Stryker, Smith, Zimmer Biomet, Bariatric, Imron Zafar, Zafar Organizations: Novo Nordisk, Abbott Laboratories, CNBC, JPMorgan, Companies, Inspire Medical Systems, Resmed, Philips, Nephew, Deutsche Bank, Madrigal Pharmaceuticals, Sagimet Biosciences, Akero Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, Madrigal Locations: U.S
☆ Pfizer makes equity investment in Caribou Biosciences
  + stars: | 2023-07-06 | by ( ) www.reuters.com   time to read: +2 min
July 6 (Reuters) - Pfizer (PFE.N) has invested $25 million to buy a minority stake in Caribou Biosciences (CRBU.O), making it the latest small biotechnology firm to attract the pharmaceutical giant's interest. The news lifted shares of Caribou more than 61% in early trade. Pfizer purchased nearly 4.7 million Caribou shares at $5.33 per share, Caribou said on Thursday, representing a premium of about 30% over Caribou's previous close price. This represents 7.64% of outstanding shares in Caribou, according to Reuters' calculation based on Refinitiv IBES data. It also made a $25 million equity investment in Akero Therapeutics (AKRO.O) last year.
Persons: Caribou, NASH, Jennifer Doudna, Raghav Mahobe, Leroy Leo, Maju Samuel Organizations: Pfizer, Caribou Biosciences, Biohaven Pharmaceutical, Akero Therapeutics, Thomson Locations: Caribou, California, Bengaluru
☆ US FDA staff flag 'serious' safety risks for Intercept's NASH treatment
  + stars: | 2023-05-17 | by ( ) www.reuters.com   time to read: +2 min
The U.S. Food and Drug Administration's (FDA) briefing document highlighted increased risk of diabetes and liver injury from using the obeticholic acid (OCA) oral tablets for the treatment of nonalcoholic steatohepatitis (NASH). "During the course of our review, FDA identified modest benefits and serious risks of OCA for treatment of NASH," the staff said in the document and listed increased risk of sludge formation in the gall bladder and imbalance of certain lipids. The staff asked the regulator's panel of outside advisors, who are meeting on Friday, to consider whether the modest benefits from using the drugs for NASH treatment outweigh the serious risks associated with it. The panel's meeting on Friday is the first such meeting for a NASH treatment. However, due to risks of serious liver injury, FDA restricted its usage in 2021 to primary biliary cholangitis patients with advanced cirrhosis, or severe liver scarring.
☆ Stocks are headed for their worst year since 2008, but some names doubled or more in 2022
  + stars: | 2022-12-29 | by ( Sarah Min | ) www.cnbc.com   time to read: +4 min
Stocks may be careening toward their worst year since 2008, but some names are completing a remarkable run after doubling or more in 2022. In 2022, the Dow Jones Industrial Average has lost 8.4%, while the S & P 500 shed 19.2%. These stocks are up more than 100% this year, and include tankers for petroleum products, energy companies such as coal firms, and biotech and pharmaceutical names, according to CNBC. Ardmore Shipping and Scorpio Tankers were the top tanker stocks, both up about 316% for the year. Energy companies came out on top in 2022 following a surge in oil and gas prices — which market participants say will remain elevated given expectations of tight supply ahead.
0 next >>
Total: 10